Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-18T16:48:28.693Z Has data issue: false hasContentIssue false

Chapter 19 - Hepatitis C virus infection

from Section III - Hepatitis and immune disorders

Published online by Cambridge University Press:  05 March 2014

Maureen M. Jonas
Affiliation:
Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital Boston, and Harvard Medical School, Boston, MA, USA
Frederick J. Suchy
Affiliation:
University of Colorado Medical Center
Ronald J. Sokol
Affiliation:
University of Colorado Medical Center
William F. Balistreri
Affiliation:
University of Cincinnati College of Medicine
Get access

Summary

Introduction

Hepatitis C virus (HCV) has emerged as an important cause of viral hepatitis in children but the actual number of infected children is underestimated. Because of the ability of this virus to establish chronic progressive infection, HCV infection is now a leading indication for liver transplantation in adults. The discovery of HCV using molecular cloning techniques in 1989 has led directly to a reduction in the number of acute HCV infections, and the establishment of detection and treatment strategies.

Virology

The virus is the prototype for the Hepacivirus genus of the family Flaviviridae. The virion is about 30–60nm in diameter. The capsid is thought to be enveloped by a lipid bilayer. The envelope contains two viral glycoproteins, E1 and E2, and the nucleocapsid contained within is composed of core protein and the viral RNA genome [1].

The genome is a 9.6 kb positive, single-stranded RNA (Figure 19.1). A single open reading frame (ORF) encodes a 3011 amino acid residue polyprotein that undergoes proteolysis to yield at least 10 individual gene products. Structural proteins (core and envelope) are encoded in the 50-quarter of the genome. The structural proteins (core, E1 and E2) are processed by host peptidase, and the non-structural (NS) proteins are subsequently cleaved by virally encoded NS2-3 and NS-3 proteases. The core protein is highly conserved and may be involved in other processes such as apoptosis, intracellular signaling, transcription, and modulation of the host immune response. Protein E2 binds specifically to host CD81, suggesting that it mediates viral entry into the cell. Unlike the core protein, E1 and E2 demonstrate considerable sequence heterogeneity from different isolates. The N-terminus of E2 contains a “hypervariable” region (HVR) HVR1 that is an important viral neutralization determinant. This region is also a T-cell determinant, able to activate helper T-cell responses during HCV infection. The sequence variability of E2 may account, at least in part, for the ability of HCV to elude the host immune system and establish persistent infection. Downstream is a small integral membrane protein, p7, which appears to function as an ion channel but also appears necessary for efficient assembly, release, and production of infectious progeny virions from liver cells.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Brass, V, Moradpour, D, Blum, HE. Molecular virology of hepatitis C virus (HCV): 2006 Update. Int J Med Sci 2006;3:29–34.CrossRefGoogle ScholarPubMed
Lauer, GM, Walker, BD. Medical progress: hepatitis C virus infection. N Engl J Med 2001;345:41–52.CrossRefGoogle Scholar
Enomoto, N, Sakuma, I, Asahina, Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77–81.CrossRefGoogle ScholarPubMed
Murakami, T, Enomoto, N, Kurosaki, M, Izumi, N, Marumo, F, Sato, C. Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 1999;30:1045–1053.CrossRefGoogle ScholarPubMed
Watanabe, H, Enomoto, N, Nagayama, K, et al. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5a correlate with ifn efficacy in hepatitis c virus genotype 1b infection. J Infect Dis 2001;183:1195–1203.CrossRefGoogle ScholarPubMed
Witherell, GW, Beineke, P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol 2001;63:8–16.3.0.CO;2-K>CrossRefGoogle ScholarPubMed
Pileri, P, Uematsu, Y, Campagnoli, S, et al. Binding of hepatitis C virus to CD81. Science 1998;282(5390):938–941.CrossRefGoogle ScholarPubMed
Ciuffreda, D, Kim, AY. Update on hepatitis C virus-specific immunity. Curr Opin HIV AIDS 2011;6:559–565.CrossRefGoogle ScholarPubMed
Ge, D, Fellay, J, Thompson, AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.CrossRefGoogle ScholarPubMed
Thomas, DL, Thio, CL, Martin, MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461(7265):798–801.CrossRefGoogle ScholarPubMed
Centers for Disease Control and Prevention. Viral Hepatitis Statistics and Surveillance. Atlanta, GA: Centers for Disease Control and Prevention, 2009 (, accessed 22 July 2013).
Centers for Disease Control and Prevention. Hepatitis C virus infection among adolescents and young adults - Massachusetts, 2002–2009. MMWR Morb Mortal Wkly Rep 2011;60:539–541.Google Scholar
Bresee, JS, Mast, EE, Coleman, PJ, et al. Hepatitis C virus infection associated with administration of intravenous immunoglobulin. JAMA 1996;276:1563–1567.CrossRefGoogle Scholar
Fischer, GE, Schaefer, MK, Labus, BJ, et al. Hepatitis C virus infections from unsafe injection practices at an endoscopy clinic in Las Vegas, Nevada, 2007–2008. Clinical Infectious Disease. 2010;51:267–273.CrossRefGoogle Scholar
Centers for Disease Control and Prevention. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men: New York City, 2005–2010. MMWR Morb Mortal Wkly Rep 2011;60:945–950.Google Scholar
Delgado-Borrego, A, Smith, LJ, Jonas, MM, et al. The underdiagnosis of pediatric hepatitis C: an emerging health care issue in Florida. Gastroenterology 2010;138:S779.CrossRefGoogle Scholar
Yeung, LTF, King, SM, Roberts, EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001;34:223–229.CrossRefGoogle ScholarPubMed
Conte, D, Fraquelli, M, Prati, D, Coluci, A, Minola, E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15 250 pregnant women. Hepatology 2000;31:751–755.CrossRefGoogle Scholar
Resti, M, Azzari, C, Mannelli, F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. BMJ 1998;317:437–441.CrossRefGoogle ScholarPubMed
Gibb, DM, Goodall, RL, Dunn, DT, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000;356:904–907.CrossRefGoogle ScholarPubMed
Mast, EE, Hwang, L-Y, Seto, D, Nolte, FS, Kelly, MG, Alter, MJ. Perinatal hepatitis C virus transmission: maternal risk factors and optimal timing of diagnosis. Hepatology 1999;30:499A.Google Scholar
National Institutes of Health. National Institutes of Health Consensus Development Conference statement: management of hepatitis C. Hepatology 2002;36(5 suppl 1):S3–S20.Google Scholar
American Academy of Pediatrics. Hepatitis C. In Pickering, LK (ed.) Red Book: 2009. Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2009, pp. 357–360.Google Scholar
Ruiz-Extremera, Á, Muñoz-Gámez, JA, Salmerón-Ruiz, MA, et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011;53:1830–1838.CrossRefGoogle ScholarPubMed
Sherman, KE, Rouster, SD, Chung, RT, Rajicic, N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adults AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831–837.CrossRefGoogle ScholarPubMed
Mallet, V, Vallet-Pichard, A, Pol, S. The impact of human immunodeficiency virus on viral hepatitis. Liver Int 2011;31:135–139.CrossRefGoogle ScholarPubMed
Weber, R, Sabin, CA, Friis-Moller, N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Int Med 2006;166:1632–1641.Google Scholar
Badizadegan, K, Jonas, MM, Ott, MJ, Nelson, SP, Perez-Atayde, AR. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998;28:1416–1423.CrossRefGoogle ScholarPubMed
Guido, M, Bortolotti, F, Leandro, G, et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol 2004;98:660–663.CrossRefGoogle Scholar
Jara, P, Resti, M, Hierro, L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003;36:275–280.CrossRefGoogle ScholarPubMed
Bortolotti, F, Verucchi, G, Cammà, C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008;134:1900–1907.CrossRefGoogle ScholarPubMed
Cesaro, S, Bortolotti, F, Petris, MG, Brugiolo, A, Guido, M, Carli, M. An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer 2010;55:108–112.Google Scholar
Strickland, DK, Riely, CA, Patrick, CC, et al. Hepatitis C infection among survivors of childhood cancer. Blood 2000;95:3065–3070.Google ScholarPubMed
Sanyal, AJ. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int 2011;31:23–28.CrossRefGoogle ScholarPubMed
Goodman, ZD, Makhlouf, HR, Liu, L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008;47:836–843.CrossRefGoogle ScholarPubMed
González-Peralta, R, Langham, MR, Andres, JM, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009;48:630–635.CrossRefGoogle ScholarPubMed
Rodrigue, JR, Balistreri, WF, Haber, B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009;48:341–347.CrossRefGoogle ScholarPubMed
Hartridge-Lambert, SK, Stein, EM, Markowitz, AJ, Portlock, CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology 2011:epub November 2011 .
Kage, M, Fujisawa, T, Shiraki, K, et al. Pathology of chronic hepatitis C in children. Hepatology 1997;26:771–775.CrossRefGoogle ScholarPubMed
Guido, M, Rugge, M, Jara, P, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998;115:1525–1529.CrossRefGoogle ScholarPubMed
Ghany, MG, Strader, DB, Thomas, DL, Seeff, LB. Diagnosis, management, and treatment of hepatitis C: an update (AASLD Practice Guideline). Hepatology 2009;49:1335–1374.CrossRefGoogle Scholar
Nelson, DR, Davis, GL, Jacobson, IM, et al. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2009;7:397–414.CrossRefGoogle Scholar
Alberti, A. Impact of a sustained virological response on the long-term outcome of hepatitis C. Liver Int 2011;31:18–22.CrossRefGoogle ScholarPubMed
González-Peralta, R, Kelly, DA, Haber, B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005;42:1010–1018.CrossRefGoogle Scholar
Wirth, S, Ribes-Koninckx, C, Calzado, MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501–507.CrossRefGoogle Scholar
Schwarz, KB, Gonzalez-Peralta, RP, Murray, KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450–458.CrossRefGoogle ScholarPubMed
Delgado-Borrego, A, Healey, D, Negre, B, et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2010;51:191–197.CrossRefGoogle ScholarPubMed
Raghunaathan, KDR, Galacki, DM, Quan, J, Mitchell, PD, Jonas, MM. Prevalence and characterization of thyroid abnormalities in children and young adults treated with combination therapy for chronic hepatitis C at a single center. Gastroenterology 2009;136(Suppl 1):A808.CrossRefGoogle Scholar
Martinot-Peignoux, M, Marcellin, P, Pouteau, M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050–1056.CrossRefGoogle ScholarPubMed
Davis, GL, Wong, JB, McHutchison, JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645–652.CrossRefGoogle ScholarPubMed
Fried, MW, Hadziyannis, SJ, Shiffman, ML, Messinger, D, Zeuzem, S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011;55:69–75.CrossRefGoogle ScholarPubMed
Jara, P, Hierro, L, de la Vega, A, et al. Efficacy and safety of peginterferon-alfa2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr Infect Dis J 2008;28:1–7.Google Scholar
Rauch, A, Kutalik, Z, Descombes, P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338–1345.CrossRefGoogle ScholarPubMed
Petta, S, Camma, C, Scazzone, C, et al. Low serum vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 2 chronic hepatitis C. Hepatology 2010;51:1158–1167.CrossRefGoogle Scholar
Patel, K, Lucas, JE, Thompson, JW, et al. High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. Hepatology 2011;53:1809–1818.CrossRefGoogle ScholarPubMed
Clark, PJ, Thompson, AJ, McHutchison, JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. Am J Gastroenterol 2011;106:38–45.CrossRefGoogle ScholarPubMed
Ghany, MG, Nelson, DR, Strader, DB, Thomas, DL, Seeff, LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433–1444.CrossRefGoogle ScholarPubMed
Gane, EJ, Roberts, SK, Stedman, CA, et al. Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. Hepatology 2009;50(Suppl):394A–395A.Google Scholar
Khaliq, S, Jahan, S, Hassan, S. Hepatitis C virus p7: molecular function and importance in hepatitis C virus life cycle and potential antiviral target. Liver Int 2011;31:606–617.CrossRefGoogle ScholarPubMed
Torresi, J, Johnson, D, Wedemeyer, H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011;54:1273–1285.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×